The short version of melanotan-2 fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-07-29. Anything still debated is marked as such rather than presented as settled.
Melanotan II binds several melanocortin receptor subtypes rather than a single target. MC1R on melanocytes drives melanin synthesis, while MC3R and MC4R participate in energy balance, appetite, and sexual response pathways. This lack of selectivity explains why reported effects extend beyond skin darkening. Substitutions at positions four and seven, including norleucine and D-phenylalanine, increase potency and resistance to peptidases. Understanding which receptor mediates which effect remains an active area of investigation.
Published human data come mostly from small, short studies rather than large controlled trials. Reported outcomes include increased skin pigmentation and, in some reports, effects on appetite and libido, but sample sizes are small and follow-up is limited. Whether long-term use produces durable pigment changes or adverse effects is not established. Because products sold outside pharmacies are not standardized, the actual content of any given vial is often unknown. Independent testing of such material is uncommon.
Melanotan II is a synthetic cyclic heptapeptide analog derived from the core sequence of alpha-melanocyte-stimulating hormone. Researchers at the University of Arizona synthesized it during the 1980s while studying pigmentation and appetite signaling. The compound is not an approved medicine in any major jurisdiction and appears mainly in laboratory and research-chemical settings. Its structure incorporates a lactam bridge between side chains, which constrains the ring and slows enzymatic breakdown relative to the natural hormone.
Outside regulated medicine, melanotan II circulates through online vendors as a research chemical, often marketed for tanning. Products sold this way vary widely in purity, concentration, and labeling accuracy, and independent testing has documented discrepancies. Published reports describe both pigment effects and adverse reactions, including nausea, flushing, and darkening of existing moles. Long-term safety data are sparse, and no large controlled trial has established a risk profile. Questions about cumulative effects on melanocytes remain unresolved in the literature.
Melanotan II is a synthetic peptide analog modeled on alpha-melanocyte-stimulating hormone, a naturally occurring signaling peptide involved in pigmentation. Its structure is a cyclic heptapeptide containing two non-natural substitutions, norleucine at position four and D-phenylalanine at position seven. These modifications resist enzymatic breakdown and extend the molecule's activity relative to the native hormone. The compound binds melanocortin receptors and is studied mainly as a pharmacological tool rather than a therapeutic product. It has never received approval as a medicine in any major jurisdiction.
The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Analog of alpha-melanocyte-stimulating hormone |
| Primary receptor family | Melanocortin receptors MC1R through MC5R | Binding is not subtype-selective |
| Development period | 1980s | Synthesized during pigmentation and appetite research |
| Regulatory status | Not an approved medicine | No major regulator has authorized human use |
| Related compound | Afamelanotide | Linear analog studied for photoprotection |
Two structural changes distinguish the synthetic peptide from the natural hormone. A norleucine residue replaces methionine at one position, and a D-configured phenylalanine replaces the natural L-form at another. Both substitutions slow enzymatic breakdown, which extends the molecule's persistence relative to the parent hormone. The lactam bridge further constrains the backbone into a stable conformation. These features are standard design strategies in peptide chemistry and are not unique to this compound; they appear across many research peptides built for improved stability.
The compound was developed in the late 1980s and early 1990s by academic researchers investigating melanocortin signaling and pigmentation. Early work explored whether synthetic analogs could reproduce effects of the natural hormone under controlled conditions. The molecule never advanced through the full regulatory pathway required for approval as a medicine. From the mid-2000s onward it appeared in unregulated consumer markets, often distributed through informal channels. That gap between research origins and commercial availability shapes how the compound is discussed today.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, the naturally occurring peptide involved in pigmentation signalling. Its sequence is conventionally written as Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, with a lactam bridge joining the aspartate side chain to the lysine side chain. The empirical formula is C50H69N15O9 and the monoisotopic mass lies near 1023.5 daltons. N-terminal acetylation and the D-configured phenylalanine both increase resistance to enzymatic breakdown compared with the parent hormone.
Pharmacologically, melanotan-2 behaves as a non-selective agonist across the melanocortin receptor family. Binding at MC1R on dermal melanocytes promotes eumelanin synthesis, which underlies the tanning response described in early human work. Activity at the centrally expressed MC4R receptor is associated with reported effects on appetite and erectile function. Because the peptide does not discriminate strongly among receptor subtypes, attributing any single observed effect to one receptor pathway is generally not possible without selective antagonists or receptor knockout models.
Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.
Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.
Regulatory treatment varies between countries. Several national medicines agencies have classified the peptide as unapproved, and customs authorities in some jurisdictions seize shipments on that basis. A few jurisdictions channel supply through prescription-only frameworks that do not list the substance by name. Because the material circulates mainly through online vendors, composition and purity are rarely verified before sale. Surveys of unapproved peptide products have reported labels that did not match measured content in a substantial fraction of samples.
=== Professional === Lisa attended her first IFBB professional competition at the 2014 Tampa Pro, where she placed 16th place. In 2015, Alina Popa became her coach and started training at the Armbrust PRO Gym. Her training paid off when she went on to win the 2015 Omaha Pro, the first time a professional British female bodybuilder won an overall professional competition since 1999.
=== Alpine Golf Course shareholders === Alpine Golf Course, located in Khlong Luang District, Pathum Thani Province, was originally owned by Nueam Chamnarnchatsakda, who donated the land to Wat Thammikaram Worawihan in 1969. In 1990, the land—designated as Sangha property (monastic land)—was sold and transferred to Alpine Real Estate Co., Ltd. and Alpine Golf and Sports Club Co., Ltd. The shareholders of these companies included Uraiwan Thienthong, wife of Sanoh Thienthong (Deputy Minister of the Interior at the time), and Chuchip Hansawat (Deputy Minister of Commerce). In 1997, the land was sold to Potjaman Shinawatra, wife of then-Prime Minister Thaksin Shinawatra, and Yongyuth Wichaidit, Deputy Permanent Secretary of the Ministry of Interior. A subsequent order revoked the Land Department's cancellation of the title deed for the land due to its Sangha property status. Later, in 2012, Thailand's National Anti-Corruption Commission (NACC) ruled that Yongyuth had acted dishonestly in the case. In 2019, both the Court of First Instance and the Court of Appeal sentenced Yongyuth to two years in prison for corrupt conduct. Currently, the two companies are owned by Potjaman and her three children, including Paetongtarn Shinawatra.
=== Lindow Man === Much about the local Iron Age history of Wilmslow was uncovered with the discovery of Lindow Man, in Lindow Moss. Preserved in the peat bogs for 2,000 years, Lindow Man is one of the most important Iron Age finds in the country. Despite a campaign to keep Lindow Man in the area, he was transferred to the British Museum and is a central feature of the Iron Age exhibition. He returned to Manchester Museum in April 2008 for a year-long exhibition.
=== International === Foreign governments said little in the days after the vote, most of them waiting for parliament to choose a prime minister. Once Anutin was returned to office on 19 March, United States Secretary of State Marco Rubio congratulated him and said the United States valued an alliance and friendship with Thailand spanning nearly two centuries, singling out law enforcement cooperation against cyber-scam networks and the modernisation of the defence relationship. Malaysian Prime Minister Anwar Ibrahim described Anutin as a "dear friend" and wrote that the two countries' "fates are like two rivers born of the same spring", pointing to trade, investment and cooperation along the border. Indian Prime Minister Narendra Modi followed the next day, saying that he looked forward to deepening the India-Thailand strategic partnership.
The role of the other BDNF receptor, p75, is less clear. While the TrkB receptor interacts with BDNF in a ligand-specific manner, all neurotrophins can interact with the p75 receptor. When the p75 receptor is activated, it leads to activation of NFkB receptor. Thus, neurotrophic signaling may trigger apoptosis rather than survival pathways in cells expressing the p75 receptor in the absence of Trk receptors. Recent studies have revealed a truncated isoform of the TrkB receptor (t-TrkB) may act as a dominant negative to the p75 neurotrophin receptor, inhibiting the activity of p75, and preventing BDNF-mediated cell death.
Sources: en.wikipedia.org
== Uranium-237 == Uranium-237 has a half-life of about 6.75 days. It decays into neptunium-237 by beta decay. It was discovered by Japanese physicist Yoshio Nishina in 1940, who in a near-miss discovery, inferred the creation of element 93, but was unable to isolate the then-unknown element or measure its decay properties.
The first genes to be definitively shown to contribute to autism were found in the early 1990s by researchers looking at gender-specific forms of autism caused by mutations on the X chromosome. An expansion of the CGG trinucleotide repeat in the promoter of the gene FMR1 in boys causes fragile X syndrome, and at least 20% of boys with this mutation have behaviors consistent with autism spectrum disorder. Mutations that inactivate the gene MECP2 cause Rett syndrome, which is associated with autistic behaviors in girls, and in boys the mutation is embryonic lethal. Besides these early examples, the role of de novo mutations in autism first became evident when DNA microarray technologies reached sufficient resolution to allow the detection of copy number variation (CNV) in the human genome. CNVs are the most common type of structural variation in the genome, consisting of deletions and duplications of DNA that range in size from a kilobase to a few megabases. Microarray analysis has shown that de novo CNVs occur at a significantly higher rate in sporadic cases of autism as compared to the rate in their typically developing siblings and unrelated controls. A series of studies have shown that gene disrupting de novo CNVs occur approximately four times more frequently in autism than in controls and contribute to approximately 5–10% of cases. Based on these studies, there are predicted to be 130–234 autism-related CNV loci.
The Colombia national football team (Spanish: Selección de fútbol de Colombia), nicknamed Los Cafeteros, represents Colombia in men's international association football. It is administered by the Colombian Football Federation (Spanish: Federación Colombiana de Fútbol), the governing body for football in Colombia. The federation has been affiliated with FIFA and CONMEBOL since 1936. Colombia have appeared at seven FIFA World Cups, first qualifying for the 1962 FIFA World Cup. Their best performance came at the 2014 FIFA World Cup, where they reached the quarter-finals for the first time; James Rodríguez won the Golden Boot after scoring six goals. Colombia have also reached the knockout stage at the 1990, 2018 and 2026 tournaments. Colombia won the 2001 Copa América as hosts, winning all six matches without conceding a goal. The team has also finished as runners-up in 1975 and 2024, and third in 1987, 1993, 1995, 2016 and 2021.
On the contrary, contrast, drugs that inhibit both MRP3/4 and BSEP (e.g., rifampicin, troglitazone, bosentan) pose greater risk for cholestasis MDR3 is another key canalicular efflux transporter that is the target of inhibition by certain drugs. MDR3 secretes phosphatidylcholine into bile canaliculi, where it form micelles with bile salts to dissolve cholesterol as well as protect hepatocyte and cholangiocytes from damage by bile salts. MDR3 inhibition leads to low phospholipid concentrations in bile that damages cholangiocytes and leads to cholestasis. Antifungal azoles such itraconazole have been shown to inhibit both MDR3 and BSEP, thus giving them higher cholestatic potential. Other MDR3-inhibiting drugs are chlorpromazine, imipramine, haloperidol, ketoconazole, saquinavir, clotrimazole, ritonavir, and troglitazone. Another target for inhibition, MRP2 is an apical efflux transporter that mainly exports bilirubin glucuronide and glutathione into bile. However, MRP2 is also the preferential route of export for certain sulfated conjugated BAs (taurolithocholic acid and glycolithocholic acid), so its inhibition could contribute to cholestasis. On the hepatocyte basolateral membrane, Na+-taurocholate cotransporting peptide (NTCP) is the major transporter of conjugated bile acids. Enterohepatic bile flow requires the concerted activity of both NTCP and BSEP, which form the major route by which BAs enter and exit hepatocytes respectively.
Sources: en.wikipedia.org
== Gene == The norepinephrine transporter gene, SLC6A2 is located on human chromosome 16 locus 16q12.2. This gene is encoded by 14 exons. Based on the nucleotide and amino acid sequence, the NET transporter consists of 617 amino acids with 12 membrane-spanning domains. The structural organization of NET is highly homologous to other members of a sodium/chloride-dependent family of neurotransmitter transporters, including dopamine, epinephrine, serotonin and GABA transporters.
there were many isolated subdisciplines within neuroscience with little contact between them many people who were interested in behaviour treated the brain as a black box consciousness was viewed as a taboo subject by many neurobiologists Crick hoped he might aid progress in neuroscience by promoting constructive interactions between specialists from the many different subdisciplines concerned with consciousness. He also collaborated with neurophilosophers such as Patricia Churchland. In 1983, as a result of their studies of computer models of neural networks, Crick and Mitchison proposed that the function of REM sleep and dreaming is to remove certain modes of interactions in networks of cells in the mammalian cerebral cortex; they called this hypothetical process "reverse learning" or "unlearning". In the final phase of his career, Crick established a collaboration with Christof Koch that led to publication of a series of articles on consciousness during the period spanning from 1990 to 2005. Crick made the strategic decision to focus his theoretical investigation of consciousness on how the brain generates visual awareness within a few hundred milliseconds of viewing a scene. Crick and Koch proposed that consciousness seems so mysterious because it involves very short-term memory processes that are as yet poorly understood. In his book The Astonishing Hypothesis, Crick described how neurobiology had reached a mature enough stage so that consciousness could be the subject of a unified effort to study it at the molecular, cellular and behavioural levels.
== Evolution == Many scientific studies throughout the past half century have used porcine aminoacylase as their model aminoacylase enzyme. The amino acid sequence and primary structure of porcine aminoacylase have been determined. Porcine aminoacylase 1 is composed of two identical heterodimeric subunits each consisting of 406 amino acids, with acetylalanine at the N-terminus of each. Porcine aminoacylase differs from human aminoacylase in structure but replicates its function. It can be inferred from this data that these two enzymes evolved from a common ancestral protein, retaining function but diverging in structure over time.
Sources: en.wikipedia.org
No regulator in a major market has approved it for human use. It appears in research settings and in products marketed outside pharmacy channels. Legal status for personal possession varies by country.
Afamelanotide is a linear analog that has received approval in some jurisdictions for a specific photoprotection indication. Melanotan II is cyclic and less selective across melanocortin receptors. The two are related but are not interchangeable in regulatory or clinical terms.
A compound that activates several receptor subtypes may produce effects beyond pigmentation. Selectivity influences which tissues respond and shapes the side-effect profile described in reports. Designing subtype-selective analogs is a stated goal of melanocortin research.
It is a synthetic cyclic peptide designed as an analog of alpha-melanocyte-stimulating hormone. It acts on melanocortin receptors and is best known from research into pigmentation. It is not an approved pharmaceutical product.